SEC Form 4 · STOCK Act

Insider buys that paid off for the people who copied them.

$ZSTK

ZeroStack Corp.

+206.0%

Michael Heinrich, Executive Chair, bought $3.5M. Filed Jul 20, 6:31 PM ET.

COPIED JUL 21

$1,000 copied at the first price after the filing (Jul 21 open, $1.66) was $3,060 30 trading days later.

Example. Of 339 buys of $100K or more filed Jun 29 to Sep 11, the median lost 5.3% and 67.8% lost money over the same 30 trading days. Not investment advice.

Officers and directors must report their own stock purchases within two business days. We list every one, largest first, with what copying it would have returned.

A free account keeps a watchlist. No password: we email you a link.

SYRSSell

Syros Pharmaceuticals, Inc.

Nancy A Simonian · Director

$36K−77.0%Nov 27
SYRSSell

Syros Pharmaceuticals, Inc.

Jason Haas · CFO

$29K−100.0%Nov 20
SYRSSell

Syros Pharmaceuticals, Inc.

Conley Chee · President and CEO

$27K−100.0%Nov 20
SYRSBuy

Syros Pharmaceuticals, Inc.

Jason Haas · CFO

$161K+407.0%Sep 12
SYRSBuy

Syros Pharmaceuticals, Inc.

Conley Chee · President and CEO

$161K+444.0%Sep 12
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$178K−81.0%Jul 2
SYRSSell

Syros Pharmaceuticals, Inc.

David Roth · Chief Medical Officer

$52K−100.0%Apr 5
SYRSBuy

Syros Pharmaceuticals, Inc.

Srinivas Akkaraju · Director

$4.0M+102.0%Dec 26
SYRSSell

Syros Pharmaceuticals, Inc.

David Roth · Chief Medical Officer

$31K−100.0%Dec 14
SYRSSell

Syros Pharmaceuticals, Inc.

David Roth · Chief Medical Officer

$29K−100.0%Aug 2
SYRSSell

Syros Pharmaceuticals, Inc.

Eric R Olson · Chief Scientific Officer

$34K−100.0%Mar 17
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$45K−1.0%Feb 18
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$53K−2.0%Feb 10
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$49K−1.0%Feb 10
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$50K−2.0%Oct 19
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$62K−2.0%Sep 16
SYRSSell

Syros Pharmaceuticals, Inc.

Eric R Olson · Chief Scientific Officer

$205K−100.0%Aug 19
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$75K−2.0%Aug 19
SYRSSell

Syros Pharmaceuticals, Inc.

Srinivas Akkaraju · Director

$2.1M−11.0%Aug 19
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$71K−2.0%Jul 17
SYRSSell

Syros Pharmaceuticals, Inc.

Srinivas Akkaraju · Director

$51KJul 6
SYRSSell

Syros Pharmaceuticals, Inc.

Srinivas Akkaraju · Director

$1.7M−10.0%Jun 25
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$52K−2.0%Jun 16
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$55K−2.0%May 15
SYRSBuy

Syros Pharmaceuticals, Inc.

Mark J Alles · Director

$89KMay 13
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$210K−6.0%Apr 17
SYRSBuy

Syros Pharmaceuticals, Inc.

Jeremy P. Springhorn · Chief Business Officer

$100K+133.0%Nov 12
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$250K−6.0%Aug 19
SYRSSell

Syros Pharmaceuticals, Inc.

Arch Venture Fund Vii, L.P. · 10% owner

$489K−1.0%Jul 17
SYRSBuy

Syros Pharmaceuticals, Inc.

Srinivas Akkaraju · Director

$4.0M+50.0%Apr 11
SYRSSell

Syros Pharmaceuticals, Inc.

Arch Venture Fund Vii, L.P. · 10% owner

$1.3M−4.0%Mar 14
SYRSSell

Syros Pharmaceuticals, Inc.

Arch Venture Fund Vii, L.P. · 10% owner

$1.1M−4.0%Mar 11
SYRSBuy

Syros Pharmaceuticals, Inc.

Srinivas Akkaraju · Director

$2.0M+25.0%Feb 2
SYRSBuy

Syros Pharmaceuticals, Inc.

Jeremy P. Springhorn · Chief Business Officer

$136KDec 15
SYRSBuy

Syros Pharmaceuticals, Inc.

Srinivas Akkaraju · Director

$992K+15.0%Dec 14
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$72K−1.0%Aug 16
SYRSSell

Syros Pharmaceuticals, Inc.

Eric R Olson · Chief Scientific Officer

$59K−100.0%Aug 8
SYRSSell

Syros Pharmaceuticals, Inc.

Eric R Olson · Chief Scientific Officer

$273K−100.0%Jul 27
SYRSSell

Syros Pharmaceuticals, Inc.

Richard A Young · Director

$72K−1.0%Jul 27
SYRSBuy

Syros Pharmaceuticals, Inc.

Amir Nashat · Director and 10% owner

$5.0M−114.0%Jul 7
SYRSBuy

Syros Pharmaceuticals, Inc.

Polaris Management Co. Vii, L.L.C. · 10% owner

$5.0M−114.0%Jul 7
SYRSBuy

Syros Pharmaceuticals, Inc.

Redmile Group, LLC · 10% owner

$5.4M−113.0%Jul 7
SYRSBuy

Syros Pharmaceuticals, Inc.

Flagship Ventures Fund Iv, L.P. · 10% owner

$5.0M+55.0%Jul 7
SYRSBuy

Syros Pharmaceuticals, Inc.

Arch Venture Fund VII LP · 10% owner

$5.0M+9.0%Jul 7
SYRSBuy

Syros Pharmaceuticals, Inc.

Robert Nelsen · Director and 10% owner

$5.0M+9.0%Jul 6
SYRSBuy

Syros Pharmaceuticals, Inc.

Aisling Capital III LP · 10% owner

$5.0M+79.0%Jul 6
SYRSBuy

Syros Pharmaceuticals, Inc.

James E Flynn · Possible Members of 10% Group, 10%

$5.0M+24.0%Jul 6

Filings come from SEC EDGAR within a minute of the SEC accepting them. Without Pro, each one unlocks 4 hours later. Not investment advice.

Questions

Where does the data come from?

Corporate insider trades come straight from SEC Form 4 filings, pulled from EDGAR within a minute of each filing. Congress trades come from STOCK Act disclosures. All of it is public and free to browse here, and Pro sees the newest filings first.

How often is it updated?

Every minute from 6 AM to 10 PM New York time on weekdays, the hours the SEC accepts filings. Pro sees each filing as it lands. Without Pro, a filing unlocks 4 hours after the SEC accepts it.

Is following insider trades legal?

Yes. Insiders are legally required to disclose their trades within a few days. Acting on those public disclosures is completely legal. Trading on private, non-public information is illegal, but that's a different thing.

What does the iPhone app add?

We're building an iPhone app that alerts you to new filings and, if you choose, copies a buy into your own brokerage after you approve it. It isn't out yet, and the waitlist is free.